Information Provided By: 
Fly News Breaks for June 10, 2016
TEVA, EGRX
Jun 10, 2016 | 12:49 EDT
RBC Capital analyst Randall Stanicky said a judge's ruling in Teva's (TEVA) favor regarding the Treanda patent fight should give a small sentiment boost to Teva while it removes a "huge uncertainty" for Eagle Pharmaceuticals (EGRX), which he sees having "momentum towards $60" per share on the news. The ruling should make it more difficult for any generic path to market and should allay investor concerns around potential headwinds from generic entrants to Bendeka, said Stanicky. RBC has Outperform ratings on Eagle and Teva.
News For EGRX;TEVA From the Last 2 Days
There are no results for your query EGRX;TEVA
